source
- Durvalumab plus enfortumab vedotin improves survival outcomes in muscle-invasive bladder cancerA recent clinical study evaluated the perioperative use of durvalumab together with enfortumab vedotin in patients with muscle-invasive bladder cancer. The topline results indicated that the combi…
- AstraZeneca reports Phase 3 trial shows Imfinzi-Padcev combo improves survival in bladder cancerAstraZeneca announced that its Phase 3 study of the immunotherapy Imfinzi combined with the antibody‑drug conjugate Padcev, developed with Pfizer and Astellas, extended overall survival for patient…